Articles tagged with Psoriasis
Research at Kyoto University found that estradiol suppresses severe skin inflammation in females compared to males, revealing its therapeutic potential. The hormone regulates immune cells and reduces IL-17A and IL-1β cytokines production.
Researchers at Scripps Research have identified a protein in sensory nerves that detects mechanical itch, which could lead to better drug treatments for chronic itch conditions. The discovery was made by Ardem Patapoutian and his team, who found that PIEZO1 is expressed in two types of sensory neurons implicated in chemical itch.
A new machine-learning tool can speed up the diagnosis of psoriatic arthritis by identifying patients up to 4 years prior to a clinician's diagnosis. The tool, PredictAI, analyzed medical records and accurately identified 32-51% of confirmed PsA patients.
Researchers found that low-density neutrophils are associated with chronic inflammation in obesity, which can lead to comorbidities like type 2 diabetes and cancer. Bariatric surgery reduces these cells in circulation, improving metabolic syndrome components.
A UC Davis Health study found that taking bile acids or treatments regulating their production levels can help control psoriasis inflammation. Bile acids inhibited skin inflammation by stopping immune T cells from producing proinflammatory protein IL-17A and blocking immune cell movement to the site.
A Michigan Medicine study combined genetic samples from patients of different ethnic backgrounds, identifying two new psoriasis genetic signals. The inclusion of South Asian subjects allowed researchers to pinpoint several genetic variations within HLA genes that are likely to play a causal role in psoriasis.
A recent study by La Jolla Institute for Immunology has identified a trio of proteins - TWEAK, TNF, and IL-17 - that control inflammation in psoriasis patients. Targeting this protein complex may lead to more effective treatments for the disease.
A new study published in the New England Journal of Medicine found that a psoriasis medicine worsened symptoms in patients with severe asthma. The trial tested risankizumab, an injectable treatment for psoriasis, and showed it did not improve asthma symptoms, but rather made them worse.
New study reveals that blocking interleukin-23 is more effective than targeting both interleukin-23 and interleukin-12 in treating psoriasis. Interleukin-12, previously thought to contribute to the disease, actually protects against it by maintaining normal skin cell function.
A study published in British Journal of Clinical Pharmacology found a potential link between blood pressure medication use and the development of psoriasis. Data from 13 studies suggests that certain types of antihypertensive medications may increase the risk of skin conditions, warranting close monitoring.
Researchers found glycerin, a natural ingredient in many skin lotions, reduces psoriasis symptoms by calming scaly patches and promoting healthy skin cell maturation. The study's results support anecdotal reports from patients with psoriasis, providing objective evidence of glycerin's effectiveness in combatting the condition.
Researchers identified a new cell type in human skin contributing to AD and psoriasis, highlighting potential therapeutic targets. The study revealed CD14+ type 3 dendritic cells co-producing IL1B and IL23A, essential for PSO pathogenesis.
A new study examining the association between type 2 diabetes mellitus and skin diseases reveals a strong link between the two conditions. The research, published in Chinese Medical Journal, found that 93.5% of individuals with T2DM had skin problems, including over 47 types of comorbid skin diseases.
A Michigan Medicine study found that altering interferon kappa levels in mice with psoriasis-like lesions reduced disease severity. The research suggests using therapies to modulate interferon states may limit inflammation in psoriasis patients.
A systematic evaluation of COVID-19 studies in patients with psoriasis and psoriatic arthritis found high risk of bias and quality issues. The median score for all studies was 47.2% indicating a high risk of bias, mainly due to selection bias.
Researchers at NYU Abu Dhabi have determined the structure of a nanobody, Nb23, using liquid state techniques. This breakthrough could lead to better understanding of its disease-fighting potential and exploration of alternative therapeutic uses.
A national survey study found that psoriasis has become more common among adults in the United States over the past two decades. The study estimated a significant increase in psoriasis prevalence from 2.4% in 2003 to 5.0% in 2021.
A study published in the Journal of Investigative Dermatology found that a Western diet rich in sugar and fat disrupts gut microorganisms, leading to psoriasis flares. Switching to a balanced diet restores gut health and suppresses skin inflammation, offering a potential solution for managing the condition.
A novel chemical blocker targeting chemokine proteins significantly reduces skin and joint inflammation in a mouse model with psoriasis and psoriatic arthritis. The study identifies CCR6 as a critical agent for joint inflammation, making it an attractive target for arthritis therapy.
Researchers discovered that immune cells change their behavior in response to a trigger, producing protein signals that cause skin lesions. This finding could lead to better treatment options for the disease by targeting early responder cells.
A modified 5:2 diet has shown promising results in reducing scaling and thickness of skin symptoms in psoriasis patients. The study found a significant reduction in Psoriasis severity after following the MIF diet, with 30% of patients reporting a decrease in itching.
A research team identified a new factor in the immune system's signal transmission that contributes to psoriasis development. The 'c-Jun' protein in dendritic cells promotes psoriatic skin inflammation, which can be alleviated by inhibiting this protein.
A recent review article published in Chinese Medical Journal explores the associations between psoriasis treatments and risks of cardiovascular diseases. The study finds that some treatments, such as TNF-α inhibitors and methotrexate, may reduce long-term cardiovascular risk, while others, like IL-12/23 inhibitors, may increase it.
A new protein purification process, known as precipitation, could significantly reduce the cost of producing antibodies for chronic diseases and COVID-19 treatment. The method eliminates the need for costly chromatography processes, making it a promising solution to drive down production costs.
Researchers have identified p62 as a multifunctional protein that influences inflammatory changes in diseased epidermis. Inhibiting p62 leads to alleviation of chronic inflammation, suggesting it as a promising therapeutic target for atopic dermatitis and psoriasis.
Researchers create detailed map of skin cells, revealing that cellular processes from development are re-activated in cells from patients with inflammatory skin disease. This study offers potential new drug targets for treating eczema and psoriasis.
A new topical treatment, benvitimod cream, has been proven safe and effective for mild-to-moderate plaque psoriasis. In a phase III clinical trial, the cream achieved a 75% decrease in psoriasis size and severity compared to pre-treatment levels.
A major register-based study demonstrates a connection between inferior physical fitness in young adults and elevated risk of the autoimmune disease psoriasis. The risk was found to be 35% higher in men who were rated as the least fit compared to those who were fittest.
Researchers identify neutrophils as potential culprits for psoriasis inflammation and keratinization, offering new directions for developing novel therapeutic approaches. The study provides mechanistic insights into the involvement of neutrophils in psoriasis pathogenesis.
A new clinical study demonstrates that a non-living strain of Prevotella histicola can treat systemic inflammation in mild to moderate psoriasis through oral delivery. The treatment showed significant reductions in Psoriasis Area Severity Index (PASI) and Lesion Severity Scores (LSS), with minimal side effects.
A global registry of psoriasis and COVID-19 patients found that over 90% of patients taking immune system drugs survived the pandemic. The risk factors for severe outcomes were similar to those in the general population, with older, male patients and those with certain health conditions being more likely to require hospital admission.
Research from the University of Pennsylvania School of Medicine found that TV ads for psoriasis and eczema medications lack diversity, particularly among racial and ethnic minorities. This underrepresentation may contribute to treatment disparities, as non-white patients are less likely to receive effective treatments.
A recent study published in Circulation: Cardiovascular Imaging Journal found that biologic therapy for psoriasis can significantly reduce high-risk plaque in heart arteries over a one-year period. The treatment was associated with an 8% reduction in coronary plaque, similar to the benefits of statin therapy.
Researchers pinpointed a single gene biomarker, nitride oxide synthase 2 (NOS2), to distinguish between atopic dermatitis and psoriasis with 100% accuracy using adhesive tape strips. The study identifies distinct immune response markers for each disease.
Researchers found that roflumilast cream significantly improved psoriasis signs and symptoms in as early as two weeks, with clear skin, itch reduction, and burden of disease improvement. The treatment showed promise for patients with plaque psoriasis lacking suitable options.
The Corrona Psoriasis Registry presents studies on real-world prescribing patterns, biologic drug effects, and COVID-19 outcomes. Longitudinal studies also report improvements in quality of life and work productivity for patients treated with biologics.
Researchers discovered an overabundance of KLK6 protein can produce skin inflammation in psoriasis, while normalizing its level can eliminate it. They also found that KLK6 plays a key role in damaging joints and bones in people with the disorder.
A new study from Umea University reveals that psoriasis patients with comorbid physical diseases experience increased mental health risks due to these associated somatic illnesses. The research indicates a higher risk of depression, anxiety, and suicide among psoriasis patients with other medical conditions.
A study of 34,000 biologic-treated patients found an increased melanoma risk compared to 135,000 conventional therapy patients. The results suggest a potential association between long-term use of biologics for inflammatory diseases and the development of melanoma.
This observational study analyzed 112 studies to examine the association between cancer risk in patients with psoriasis or psoriatic arthritis. The findings suggest that these patients may be at higher risk of specific cancers, including melanoma and non-melanoma skin cancers.
A study by UC Davis Health researchers found that a Western diet rich in fat and sugar can induce inflammatory skin diseases like psoriasis. The diet's components, rather than obesity, may lead to skin inflammation and its development.
Researchers discover that targeting VEGFA signaling in the epidermis prevents psoriasis development, including immune cell infiltration and blood vessel formation. A therapeutic anti-Nrp1 antibody demonstrates significant therapeutic benefit in treating psoriatic disease.
Researchers at Brigham and Women's Hospital have uncovered a novel pathway explaining why skin thickens in psoriasis, suggesting new strategies for developing therapies. The study found a defect in the epigenetic covering that resulted in loss of DNA methylation hydroxymethylation mark, leading to dysregulated stem cell behavior.
Researchers analyzed 3,723 adults and found significant sex differences in the relationship between psoriasis and metabolic disorders. Women with psoriasis were more likely to develop metabolic syndrome and diabetes than their male counterparts.
A research team at Trinity College Dublin has discovered that PKM2 is a central 'on' switch for immune cells involved in psoriasis and multiple sclerosis. Interfering with PKM2 blocks these cells and limits inflammation, offering new potential treatments for these diseases.
Researchers found that psoriasis onset age determines whether arthritis starts first, with a 65-month delay for arthritis onset after psoriasis. Early-onset psoriasis is strongly associated with arthritis onset, suggesting a different subgroup of PsA patients.
A systematic review and meta-analysis of 58 studies found that people with psoriasis are at a higher risk of developing and dying from cancer. The research suggests a potential underlying biological mechanism for the increased cancer risk in patients with psoriasis.
New research reveals a striking proportion of psoriasis patients remain untreated, with doctors investing too little time into patients. The study found that over half of patients are not currently visiting a physician to help with treatment, indicating a need for improved care and patient engagement.
Researchers found a significant association between psoriasis and non-alcoholic fatty liver disease (NAFLD) severity, with higher psoriasis severity linked to more severe hepatic damage. The study suggests that patients with both conditions should be closely monitored and managed to prevent worsening of both diseases.
Researchers used virtual patients and in silico clinical studies to evaluate the effectiveness of blue light therapy for psoriasis. They found that this approach can accurately capture patient variability and improve treatment response.
Researchers found that anti-inflammatory biologic therapies can significantly reduce coronary inflammation in psoriasis patients, using a novel imaging biomarker. The study has implications for other chronic inflammatory diseases, such as lupus and rheumatoid arthritis.
A survey of psoriasis patients found that they often turn to complementary and alternative therapies, such as vitamins D and B12, when traditional medications fail. Despite limited evidence supporting these treatments, patients report therapeutic benefits from Dead Sea treatments.
A study found that patients taking newer, targeted biologics for psoriasis have a decreased risk of serious infection compared to older medications. The researchers analyzed large insurance claims databases and found that certain biologics like apremilast, etanercept, and ustekinumab had a lower risk of infection.
Two studies found a significant association between psoriasis and an increased risk of mental health disorders, including depression and anxiety, in Denmark and South Korea. The research highlights the importance of addressing the mental health needs of individuals with chronic skin conditions like psoriasis.
A new study from the Norwegian University of Science and Technology found that higher body mass index (BMI) is linked to an increased risk of developing psoriasis. The observational study analyzed data from over 750,000 individuals and found a 9% increase in risk for each whole BMI unit increase.
Research published by the European Society of Cardiology found that biologic drugs used to treat severe psoriasis can improve coronary artery plaque, reducing the risk of heart attacks. The study showed an 8% reduction in total and non-calcified coronary plaque burden among patients taking biologic therapy.
Treating psoriasis with biologic drugs has been shown to reduce early plaque buildup in arteries, restricting blood flow and leading to heart attacks and stroke. The study highlights the potential of immunotherapies in reducing cardiovascular disease risks.
Researchers at the University of Birmingham have discovered a protein fragment called ?N-JARID2 that regulates skin cell differentiation. The finding holds promise for developing new gene therapies for psoriasis and other skin conditions caused by hyper-proliferation of skin cells.
Researchers have discovered a lipid called phosphatidylglycerol (PG) that may help restore healthy skin turnover in people with psoriasis. PG reduced inflammation and raised skin lesions when applied topically to a mouse model of psoriasis, suggesting it could be a new treatment option.
The LEO Foundation Skin Immunology Research Center will bring together leading researchers to provide new knowledge for better diagnoses and treatments of psoriasis and eczema. The center aims to strengthen the immune system's fight against over 3,000 known skin diseases.